TY - JOUR T1 - Multiplexed, quantitative serological profiling of COVID-19 from a drop of blood by a point-of-care test JF - medRxiv DO - 10.1101/2020.11.05.20226654 SP - 2020.11.05.20226654 AU - Jacob T. Heggestad AU - David S. Kinnamon AU - Lyra B. Olson AU - Jason Liu AU - Garrett Kelly AU - Simone A. Wall AU - Cassio M. Fontes AU - Daniel Y. Joh AU - Angus M. Hucknall AU - Carl Pieper AU - Ibtehaj A. Naqvi AU - Lingye Chen AU - Loretta G. Que AU - Thomas Oguin III AU - Smita K. Nair AU - Bruce A. Sullenger AU - Christopher W. Woods AU - Gregory D. Sempowski AU - Bryan D. Kraft AU - Ashutosh Chilkoti Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/07/2020.11.05.20226654.abstract N2 - Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage the COVID-19 pandemic. Here, we report on a microfluidic, multiplexed POC test that can profile the antibody response against multiple SARS-CoV-2 antigens—Spike S1 (S1), Nucleocapsid (N), and the receptor binding domain (RBD)—simultaneously from a 60 µL drop of blood, plasma, or serum. We assessed the levels of anti-SARS-CoV-2 antibodies in plasma samples from 19 individuals (at multiple time points) with COVID-19 that required admission to the intensive care unit and from 10 healthy individuals. This POC assay shows good concordance with a live virus microneutralization assay, achieved high sensitivity (100%) and specificity (100%), and successfully tracked the longitudinal evolution of the antibody response in infected individuals. We also demonstrated that we can detect a chemokine, IP-10, on the same chip, which may provide prognostic insight into patient outcomes. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed in the fight against COVID-19 by democratizing access to laboratory quality tests.Competing Interest StatementImmucor Inc., has acquired the rights to the D4 assay on POEGMA brushes for in vitro diagnostics from Sentilus Inc. (cofounded by AC and AMH).Funding StatementAC acknowledges the support of the National Science Foundation (Grant No. CBET202936); the National Cancer Institute through grants P30-CA014236, R01-CA248491, UH3-CA211232; Department of Defense United States Special Operations Command (Grant No. W81XWH‐16‐C‐0219); Defence Academy of the United Kingdom (Grant No. ACC6010469); and the Combat Casualty Care Research Program (JPC‐6) (Grant No. W81XWH‐17‐2‐0045). BDK receives funding from NHLBI (K08HL130557). We thank Dr. David Montefiori for providing laboratory space to complete the clinical validation studies. We also thank Rebecca Sahm for completing live SARS-CoV-2 microneutralization assays, which were performed in the Virology Unit of the Duke Regional Biocontainment Laboratory, which received partial support for construction from the NIH/NIAD (UC6AI058607; GDS). We thank the nurses in the intensive care units of Duke University Hospital for collecting the blood samples used for this study and thank Dr. Patty Lee for supporting the ICU Biorepository. We thank Dr. Tony Moody for access to the pre-pandemic negative control samples used in this study, Dr. Thomas Denny for providing access to BSL2+ laboratory facilities to run the pre-pandemic negative samples, and Heidi Register for assistance with testing the negative samples on the DA-D4 POCT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:De-identified heat-inactivated EDTA plasma samples were accessed from the Duke COVID-19 ICU biorepository (Pro00101196, PI Bryan Kraft) via an exempted protocol approved by the Duke University Institutional review board (Pro00105331, PI Ashutosh Chilkoti). The exempt protocol was used to test all other negative control pre-pandemic samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are included in the manuscript and supplementary information ER -